Skip Navigation

European Heart Journal 1996 17(Supplement E):42-48; doi:10.1093/eurheartj/17.suppl_E.42
Copyright © 1996 by the European Society of Cardiology.
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Topol, E. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Topol, E. J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1996 1996 The European Society of Cardiology

Early myocardial reperfusion: An assessment of current strategies in acute myocardial infarction

E. J. Topol

Department of Cardiology and the Joseph J. Jacobs Center for Thrombosis and Vascular Biology, Cleveland Clinic Foundation Cleveland, Ohio, U.S.A.

Correspondence: Eric J. Topol, MD, Desk F25, Department of Cardiology, 9500 Euclid Avenue, Cleveland Clinic Foundation, Cleveland, Ohio 44195, U.S.A.

Early, complete, and sustained myocardial reperfusion is the principal goal of thrombolytic therapy. Unfortunately, the majority of patients treated today experience substantial delay before the initiation of thrombolytic therapy and, once treated, demonstrate suboptimal results of coronary thrombolysis. This is attributable, in part, to the underlying thrombus, which is platelet rich and resistant to plasminogen activators, and to the pro-thrombotic effects of fibrinolytics, which have no favourable effect on thrombin. Future therapeutic interventions will focus on improved reperfusion. Pharmacological strategies including novel plasminogen activators, direct thrombin inhibitors, and platelet glycoprotein IIb/IIIa inhibitors have all generated encouraging early clinical trial data and await further study. Mechanical reperfusion therapy with primary balloon angioplasty is particularly effective; its use is associated with the establishment of more complete infarct vessel patency than are thrombolytics. Considerable potential for the improvement of current reperfusion-directed therapy exists.

Key Words: Acute myocardial infarction • myocardial reperfusion • thrombolysis • coronary thrombosis • angioplasty • thrombin inhibitors • platelet aggregation


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.